Trial Profile
A Phase 1, Randomized, Double-blind, Vehicle And Active Comparator-controlled, Psoriasis Plaque Test Study To Assess Safety, Tolerability, And Psoriatic Skin Infiltrate Thickness Following Repeated, Topical Doses Of Pf-06763809 Solution In Subjects With Mild To Moderate Chronic Plaque Psoriasis
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Oct 2021
Price :
$35
*
At a glance
- Drugs PF 06763809 (Primary) ; Betamethasone; Calcipotriol
- Indications Plaque psoriasis
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Pfizer
- 05 Apr 2019 Status changed from active, no longer recruiting to completed.
- 15 Mar 2019 Planned End Date changed from 21 Mar 2019 to 20 Mar 2019.
- 15 Mar 2019 Status changed from recruiting to active, no longer recruiting.